Luis A. Llano-De

Santiago De Compostela, GA, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 143 publications

Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Moderate-to-Severe Asthma, Type 2 Inflammation, and Nocturnal Awakenings: The MORPHEO Randomized Controlled Trial.

Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Moderate-to-Severe Asthma, Type 2 Inflammation, and Nocturnal Awakenings: The MORPHEO Randomized Controlled Trial.

Journal: Journal of investigational allergology & clinical immunology

Published: June 29, 2026

A Retrospective Multicenter Cohort Study on the Effectiveness of Triple Inhaled Therapy in Severe Asthma.

A Retrospective Multicenter Cohort Study on the Effectiveness of Triple Inhaled Therapy in Severe Asthma.

Journal: Journal of investigational allergology & clinical immunology

Published: May 05, 2026

Temporal trends in baseline severity and 12-month response to mepolizumab in severe asthma: The TYREX multicentre real-world study in Spain (2017-2024).

Temporal trends in baseline severity and 12-month response to mepolizumab in severe asthma: The TYREX multicentre real-world study in Spain (2017-2024).

Journal: Respiratory medicine

Published: March 03, 2026

Baseline Composite Score for 12-Month Clinical Remission in Biologic-Treated Severe Asthma: Development of the Base4Score.

Baseline Composite Score for 12-Month Clinical Remission in Biologic-Treated Severe Asthma: Development of the Base4Score.

Journal: Biomedicines

Published: February 11, 2026

Association of Easier Biologic Access with Remission and Other Clinical Outcomes in Severe Asthma: A Global Real-World Study.

Association of Easier Biologic Access with Remission and Other Clinical Outcomes in Severe Asthma: A Global Real-World Study.

Journal: Journal of asthma and allergy

Published: February 10, 2026

Advancing in precision asthma management: The Treat-to-Target by Treatable Traits (T4) framework.

Advancing in precision asthma management: The Treat-to-Target by Treatable Traits (T4) framework.

Journal: Respiratory medicine

Published: February 06, 2026

Defining Minimal Clinical Disease Activity and Remission in Severe Asthma: A Modified Delphi Consensus.

Defining Minimal Clinical Disease Activity and Remission in Severe Asthma: A Modified Delphi Consensus.

Journal: The journal of allergy and clinical immunology. In practice

Published: December 19, 2025

Defining minimal clinical disease activity and remission in severe asthma: a modified Delphi consensus.

Defining minimal clinical disease activity and remission in severe asthma: a modified Delphi consensus.

Journal: The journal of allergy and clinical immunology. In practice

Published: December 19, 2025

Multidomain clinical and biological remission with tezepelumab in severe asthma: a 12-month multicentre real-world study.

Multidomain clinical and biological remission with tezepelumab in severe asthma: a 12-month multicentre real-world study.

Journal: Respiratory research

Published: December 11, 2025

Biologics Use in Eosinophilic Lung Disease: Controversies and Consensus.

Biologics Use in Eosinophilic Lung Disease: Controversies and Consensus.

Journal: The journal of allergy and clinical immunology. In practice

Published: November 13, 2025

Severe asthma: an indirect, subtle killer.

Severe asthma: an indirect, subtle killer.

Journal: The European respiratory journal

Published: November 10, 2025

Development and validation of the Risk of Exacerbation in Severe Asthma (RESA) model.

Development and validation of the Risk of Exacerbation in Severe Asthma (RESA) model.

Journal: The journal of allergy and clinical immunology. In practice

Published: October 13, 2025

Showing 1-12 of 143

Last Updated: 09/26/2026